Ask AI
Management of HER2pos GEA

CE / CME

Management of a Patient With HER2-Positive Advanced Gastroesophageal Adenocarcinoma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: February 09, 2026

Expiration: August 08, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Based on the phase III HERIZON-GEA-01 trial, which HER2 testing results would make a patient with newly diagnosed locally advanced or metastatic GEA eligible to receive zanidatamab in combination with chemotherapy with or without tislelizumab?

2.

When counseling patients with newly diagnosed HER2-overexpressing metastatic GEA requiring treatment, which of the following would you tell them was significantly improved with zanidatamab plus tislelizumab and chemotherapy vs trastuzumab plus chemotherapy in the phase III HERIZON-GEA-01 trial for patients with previously untreated HER2-overexpressing unresectable locally advanced or metastatic GEA?